MONALISA A SIOPEN pragmatic clinical trial to MOnitor NeuroblastomA relapse with LIquid biopsy Sensitive Analysis
- Coordinator
- St. Anna Kinderkrebsforschung GmbH, Austria
- Runs
- 1 January 2024 to 31 December 2028
- Status
- Running
- EU funding
- €7.2m
- Total cost
- €7.2m
- Partners
- 25 organisations in 11 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101137028
What the project is doing
In the project's own words, from its summary on CORDIS.
High-risk neuroblastoma accounts for 15% of cancer related-deaths in children. Half of the >1500 patients yearly diagnosed with neuroblastoma in the EU have high-risk disease, which will relapse or progress in half these cases after first-line treatment. Relapsed neuroblastoma is aggressive and often therapy-resistant. Monitoring for disease relapse and therapy response is crucial for the survival chance of these patients.
The current standard-of-care for monitoring are imaging technologies and bone marrow assessment, which are costly, invasive and a burden for children, who often require anesthesia. These drawbacks limit how often is monitored. More sensitive, less invasive and less toxic monitoring techniques are needed. The mutational spectrum often changes in recurring tumors, which may explain therapy resistance and provide additional druggable targets.
Imaging, however, provides no information about molecular characteristics. Liquid biopsy tests are minimally invasive, allow frequent sampling and sensitively detect tumor molecular markers in tumor-derived DNA and messenger RNA circulating in peripheral blood. MONALISA aims to close existing gaps and establish liquid biopsies as standard-of-care to monitor relapsed/refractory neuroblastoma, as a blueprint for other pediatric cancers.
Reliable, early assessment of molecular progression or relapse is the main aim of the pragmatic randomized clinical trial proposed in MONALISA. We develop a digital decision support tool to help oncologists use the new monitoring and apply patient-reported outcomes to integrate patient viewpoints and assess the effect of minimally invasive, liquid biopsy diagnostics on quality of life. We will establish whether events can be detected earlier using liquid biopsy monitoring, and whether better overall survival is enabled by earlier diagnosis and treatment interventions.
This essential step towards personalized medicine will support reliable disease monitoring under treatment. “This action is part of the Cancer Mission cluster of projects on ‘‘Diagnostics and Treatment (diagnostics).”
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| St. Anna Kinderkrebsforschung GmbH | Wien | Austria | Coordinator |
| Ait Austrian Institute of Technology GmbH | Wien | Austria | Participant |
| Esd - Evaluation Software Development GmbH | Innsbruck | Austria | Participant |
| Labdia Labordiagnostik GmbH | Wien | Austria | Third party |
| Medizinische Universitat Innsbruck | Innsbruck | Austria | Participant |
| Siopen Verein Zur Forderung Der Neuroblastomforschung | Wien | Austria | Participant |
| Interuniversitair Micro-Electronica Centrum | Leuven | Belgium | Participant |
| Siop Europe | Bruxelles / Brussel | Belgium | Participant |
| Universiteit Gent | Gent | Belgium | Participant |
| Vib Vzw | Zwijnaarde - Gent | Belgium | Associatedpartner |
| Fakultni Nemocnice Motol a Homolka | Praha 5 | Czechia | Participant |
| Charite - Universitaetsmedizin Berlin | Berlin | Germany | Participant |
| Eberhard Karls Universitaet Tuebingen | Tuebingen | Germany | Participant |
| Ethniko Kai Kapodistriako Panepistimio Athinon | Athina | Greece | Participant |
| Geniko Nosokomeio Paidon Athinon I Agia Sofia | Athina | Greece | Participant |
| Fundacio Hospital Universitari Vall D'hebron - Institut De Recerca | Barcelona | Spain | Participant |
| Institut Curie | Paris | France | Participant |
| Institut Gustave Roussy | Villejuif | France | Participant |
| Children's Health Ireland | Dublin | Ireland | Participant |
| Istituto Giannina Gaslini | Genova | Italy | Participant |
| Prinses Maxima Centrum Voor Kinderoncologie BV | Utrecht | Netherlands | Participant |
| Stichting Amsterdam Umc | Amsterdam | Netherlands | Participant |
| Institute of Cancer Research: the Royal Cancer Hospital Lbg | London | United Kingdom | Associatedpartner |
| Solving Kids Cancer UK Ltd | London | United Kingdom | Associatedpartner |
| University of Leeds | Leeds | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI